ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

Denosumab, A New Osteoporosis Mitigation Drug

Updated on September 10, 2009

Monoclonal Antibody

What is Denosumab?

Denosumab is a monoclonal antibody that prevents the formation of a protein called RANKL in osteoclasts. Osteoclasts are the cells that the body manufactures to break down bone for eventual replacement. Think of this as the body's bone remodeling process. Denosumab is currently in trials, but the results of these trials are so far encouraging.

Denosumab has a different way of working than currently marketed osteoporosis drugs including Fosamax (Merck), Actonel (Proctor & Gamble Pharmaceuticals), Forteo (Eli Lilly), Reclast (Novartis) and Boniva (Roche). The down side to these other drugs is the frequency of injection/administration ranging from daily to weekly doses. Denosumab, by contrast, would be injected twice a year.

One trial* included 7,868 women, aged 60 to 90, with moderate to severe osteoporosis. A second trial, included 912 men with prostate cancer at increased spinal fracture risk due to cancer hormone therapy. Both trials are double-blind studies in which half those tested were given a placebo and the other half denosumab.

In the women's trial 68% of those receiving the drug had reduced spine fractures and 40% fewer hip fractures. In the men's trial 62% had fewer spine fractures as compared to those men given a placebo.

* As with any new drug trials are paid for by the manufacturer.

How it Works.

Fosamax, Actonel, Reclast and Boniva all prevent the formation of osteoclasts.

Denosumab, by contrast, binds to a protein called RANKL which is used to activate osteoclasts in the body. Since denosumab binds to this protein it's use by osteoclasts to break down bone is greatly reduced. The drug does not prevent the formation of osteoclasts, unlike the above mentioned drugs, just inhibits their effectiveness.

RANKL also has a role in TCell immune response. For this reason the FDA may require Amgen to continually report on denosumab even if approved for use by prescription.

Denosumab may be responsible for eczema in some trial participants.

The drug will also have to be closely monitored for long term immune response effects. This is because RANKL is a component of the TCell outer wall.

Advantages of Denosumab

In the two trials Denosumab did not demonstrate a risk of infection or cancer, unlike other osteoporosis drugs. Denosumab also wasn't linked to osteonecrosis of the jaw, sometimes called "jawbone death."

Denosumab's safety profile "appeared excellent" in the prostate cancer study; the study was the first large study of spinal fracture prevention in men taking prostate cancer hormone treatment.

Finally, denosumab can be given as an injection only twice a year. This means patients are less likely to forget or miss a dose and can be given the drug by a nurse or nurse practitioner.

Disadvantages of Denosumab

Eczema and severe cases of a skin infection called cellulitis were more common in women taking denosumab in the first study, though the reasons for this remain unclear.

Also, because this is a new drug based on monoclonal anti-body research, with high cost per unit to produce, the drug may be cost prohibitive to all, but the few who can afford it*.

Denosumab's effectiveness may fall off to zero levels after three to four years. This is true of all other osteoporosis drugs currently on the market.

* A spokesperson for Amgen promised that the company would do it's best to make the product affordable.


Amgen ("portmanteau" of Applied Molecular Genetics) is a featured company in Jim Collin's book "Built to Last."

Amgen is a publicly traded company located in Thousand Oaks California. It currently employees 14,000 persons making it the second largest employer in Ventura County; second only to the United States Navy in the area.

The author of this article does not work for or own stock in (either directly or indiretly) Amgen Corporation, but does find the company's philosophy and history of revolutionary drugs fascinating.


  • Osteoclast: A cell who's function is to destroy bone.
  • Osteoblast: A cell who's function is to create bone.
  • Monoclonal: Replication of a cell from one ancestral cell. The cell is "encourage" to repeatedly divide; in the process creating many new cells.
  • Antibodies: A protein that binds to specific foreign bodies for the purpose of targeting them for elimination from the body. Antibodies typically bind to viruses and bacteria. Antibodies are produced by the white blood cell.
  • Antigen: Antibody Generator. A substance that prompts the generation of Antibodies.


Submit a Comment

  • LiamBean profile imageAUTHOR


    9 years ago from Los Angeles, Calilfornia

    Apparently polio is NOT cured. See

  • LiamBean profile imageAUTHOR


    9 years ago from Los Angeles, Calilfornia

    Not much I can add to what you are saying Duck.

  • profile image

    opinion duck 

    9 years ago

    Interesting, but it appears to be another continuation of treatment rather than cure.

    As far as I know, the polio vaccine was the last cure from the medical world. This was before the drug companies were corporate powers that they are today. I see a correlation between lack of cures and the rise of the drug companies.

    As long as drug companies are corporations for profit and patents and more patents are created there will never be cures. Cures and profits are going in different directions.

    There is no cure for Eczema either, just very unsuccessful and costly treatments.


This website uses cookies

As a user in the EEA, your approval is needed on a few things. To provide a better website experience, uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at:

Show Details
HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
LoginThis is necessary to sign in to the HubPages Service.
Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
AkismetThis is used to detect comment spam. (Privacy Policy)
HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the or domains, for performance and efficiency reasons. (Privacy Policy)
Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
MavenThis supports the Maven widget and search functionality. (Privacy Policy)
Google AdSenseThis is an ad network. (Privacy Policy)
Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
Index ExchangeThis is an ad network. (Privacy Policy)
SovrnThis is an ad network. (Privacy Policy)
Facebook AdsThis is an ad network. (Privacy Policy)
Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
AppNexusThis is an ad network. (Privacy Policy)
OpenxThis is an ad network. (Privacy Policy)
Rubicon ProjectThis is an ad network. (Privacy Policy)
TripleLiftThis is an ad network. (Privacy Policy)
Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)